Solid Organ Transplantation Pharmacy Specialty Certification (BCTXP)
Target Population: Pharmacists who evaluate and provide pharmacotherapy to patients who are donors, candidates, or recipients of solid organ transplants.
Program Purpose: To validate that the pharmacist has the advanced knowledge, skills, and experience to optimize outcomes by managing complex medication regimens for patients who are donors, candidates, or recipients of solid organ transplants.
Currently there are more than 390 BPS Board-Certified Transplant Pharmacists.
Solid Organ Transplantation Pharmacy Council Members
The purpose of the BPS Specialty Councils is to develop standards and eligibility requirements for board certification, develop examinations and passing standards for certification, and review and approve professional development programs for recertification of board-certified pharmacists. Specialty council members are at the heart of the peer-reviewed and peer-developed nature of BPS Board Certification.
Dr. Bernard divides her time between administrative leadership as the Senior Clinical Manager supporting Solid Organ Transplant, Cardiovascular Surgery, and the Neurosciences ICU as well as maintaining a clinical practice within solid organ transplant at Mayo Clinic. She received her Doctor of Pharmacy degree from Washington State University; PGY1 residency at Hennepin County Medical Center in Minneapolis, Minnesota; and PGY2 Solid Organ Transplant residency at Houston Methodist Hospital in Houston, Texas. Dr. Bernard has experience working in investigation, regulatory research, and academia at Erasmus University Medical Center in the Netherlands. She founded the Quality Assurance and Performance Improvement role and Solid Organ Transplant PGY2 Pharmacy Residency Program in Rochester, MN. Dr. Bernard is an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine, Fellow Member with the Mayo Clinic Academy of Educational Excellence, and has received the honor of Associate Appointment for unusually important contributions to the practice, research, and educational activities of Mayo Clinic.
Evan was born in the small town of La Grande, Oregon and spent much of his formative years in the Pacific Northwest. He graduated from Gonzaga University with a BS in biology and then went to University of California San Francisco (UCSF) for his Doctor of Pharmacy degree. His pharmacy practice residency was at the University of Washington (UW) in Seattle, after which he worked as a Transplant/ICU clinical pharmacist at UCSF for 1 year before moving back to Seattle to work as a Solid Organ Transplant Pharmacist on the abdominal transplant team at UW, where he stayed for 13 years before being recruited to his first role in industry as a transplant Medical Science Liaison (MSL). His background as a transplant clinical pharmacist gives him a comprehensive understanding of the patient journey and turned him into a fierce patient advocate. He aims to help transform transplantation by bridging science and practice, translating frontline patient care experience into product development and scientific engagement strategies that address significant unmet needs in organ rejection, graft-versus host disease, immunosuppression burden, and long-term outcomes. In his spare time he is an outdoor enthusiast, skier, trail runner, and builder.
I went to St. Johns University in Queens, New York for my undergraduate degree in Pharmacy in 1993. I achieved my Doctor of Pharmacy degree at University of Florida in 1999. I started my clinical Pharmacy career as an internal medicine pharmacist, transitioned to critical care and for the past 15 years as a solid organ transplant pharmacist. My interest is in one on one education of pharmacy students and residents to expose them to the field of solid organ transplant, biostatistics and publications.
Mary Moss Chandran is a Medical Science Liaison with Eli Lilly, specializing in cardiometabolic health. In this role, she engages with healthcare professionals and scientific leaders to advance evidence-based understanding of cardiometabolic diseases and therapeutic innovation.
She currently holds an adjunct associate professor appointment and serves as course director for the transplant elective at the UNC Eshelman School of Pharmacy.
Previously, Dr. Chandran served as a clinical pharmacist practitioner specializing in abdominal solid organ transplantation, delivering care in outpatient transplant clinics at the University of North Carolina Hospitals and Clinics.
Prior to her UNC role, she was a clinical pharmacist specialist in pediatric solid organ transplant at Children’s Hospital Colorado and a clinical pharmacist specialist in solid organ transplant at the University of Maryland Medical Center, supporting both abdominal and cardiothoracic transplant populations.
Dr. Chandran completed her PGY1 pharmacy practice and PGY2 solid organ transplant pharmacy residencies at the University of North Carolina Medical Center. She earned her Doctor of Pharmacy from the University of California San Diego Skaggs School of Pharmacy (Class of 2012) and holds a Bachelor of Science in human biology from the University of California San Diego.
She is board-certified as a Board Certified Transplant Pharmacist (BCTXP) and a Board Certified Pharmacotherapy Specialist (BCPS).
Feist graduated from University of Nebraska Medical Center in 2005 and completed her residency training at UC San Diego Health. Following her residency, she served as a Pharmacist Specialist in Solid Organ Transplantation at UC San Diego Health focusing on heart and lung transplantation in both inpatient and ambulatory care settings. In this role, she successfully implemented and expanded clinical pharmacy services across all transplant programs at UCSD. She was the founding chair for the UC Wide Solid Organ Transplant Pharmacist Collaborative Committee providing a network for transplant pharmacists at all University of California campuses. She helped develop the PGY2 Solid Organ Transplant Residency at UC San Diego Health acting as the director for nine years. Feist is currently practicing as a Clinical Professor at University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences. In addition to teaching, she continues to provide patient care in the ambulatory setting for both the lung and heart transplant programs at UC San Diego Health. Her research focuses on clinical outcomes in transplantation, specifically studying pharmacokinetics, drug interactions and adverse effects.
Karen Khalil is the Senior Project Manager in Xenotransplant at NYU Langone Health, where she facilitates and oversees the ongoing xenotransplant research at the institution. This includes the first-in-human clinical xenotransplantation trials. She received her Bachelor of Science and Doctor of Pharmacy degrees from Northeastern University in Boston. She completed a PGY1 Pharmacy Residency Program at Lahey Hospital & Medical Center in Burlington, MA where her interest in solid organ transplant began. She then completed a PGY2 in Solid Organ Transplant at University of Illinois at Chicago and joined the NYU Langone Health Transplant Team in 2018 where she managed kidney, liver, and pancreas transplant recipients before transitioning into her current role.
Dr. Nicholas Lange is currently employed as a Regional Medical Liaison for Calliditas Therapeutics covering the Northeast US territory. Prior to his recent transition into the pharmaceutical industry, he practiced as a Clinical Pharmacy Manager at NewYork-Presbyterian Hospital where he supported the adult kidney/pancreas transplant program at Columbia University Medical Center from 2017-2025. He also served as the Residency Program Director for the NewYork-Presbyterian Hospital PGY2 Solid Organ Transplant Residency Program. While in practice, he published extensively on solid organ transplant pharmacotherapy , with a particular focus on the assessment of complex drug-drug interactions and evaluation of real-world outcomes associated with novel therapeutics.
Leick is the Pharmacist Program Coordinator for Solid Organ Transplantation at Nebraska Medicine and a Clinical Assistant Professor at the University of Nebraska Medical Center College of Pharmacy. She also serves as a Pharmacist Specialist for hepatology, intestinal rehabilitation, and adult liver and intestinal transplantation. Leick received her Doctor of Pharmacy degree from the University of Nebraska Medical Center and completed her PGY1 Pharmacy Practice and PGY2 Solid Organ Transplant residencies at Duke University Hospital in Durham, North Carolina.
Megan Moravec is a Clinical Pharmacy Specialist with Pediatric Nephrology and Solid Organ Transplant at Cohen Children’s Medical Center, a division of Northwell. She received her Doctor of Pharmacy at the University of Connecticut School of Pharmacy and completed a PGY-1 Pharmacy Residency at Stony Brook University Hospital. She worked as a pediatric pharmacist at her current hospital and transitioned into her current role when the pediatric kidney transplant program began in 2017. The intricacies of a specialty within a specialty has always kept her motivated to push for better care for vulnerable patient populations. She currently provides patient care to pediatric nephrology patients in the inpatient and ambulatory environments. Dr. Moravec has a professional interest in transitions of care with a focus on discharge from hospitalization as well as expanding telehealth services
Simard is a Clinical Pharmacist Specialist for the kidney and pancreas transplant programs at Vanderbilt University Medical Center. She received her Doctor of Pharmacy degree from Concordia University Wisconsin School of Pharmacy and completed a PGY1 Pharmacy Residency at Aurora Health Care Metro, Inc. She completed her PGY2 Solid Organ Transplant residency at the University of Michigan Health System. She currently serves as the Residency Program Director for the PGY2 Solid Organ Transplant Pharmacy Residency at Vanderbilt University Medical Center.
Summers is an abdominal transplant pharmacist at the Ohio State University Wexner Medical Center in Columbus, Ohio. He received his Doctor of Pharmacy from Wingate University School of Pharmacy near Charlotte, North Carolina. He then went on to do a PGY1 Pharmacy Practice Residency at Methodist University Hospital in Memphis, Tennessee and a PGY2 Transplant Pharmacy Residency at Duke University Hospital in Durham, North Carolina. Summers has previously written several transplant publications and has also served as a content editor for the Infectious Disease Pharmacotherapy Self Assessment Program modules. His professional interests include calcineurin minimization/withdrawal, cytomegalovirus, hepatitis C, and transplant quality improvement. In his free time he enjoys ultrarunning, trail running, hiking, lifting weights, movies, and board games.
Yakubu is a Solid Organ Transplant Pharmacy Specialist at Virginia Commonwealth University Health System and an Assistant Professor of Pharmacy and Surgery at Virginia Commonwealth University. He founded the PGY-2 Solid Organ Transplant Pharmacy Residency Program at Virginia Commonwealth University Health System, and currently serves as the Residency Program Director. Yakubu received both his Bachelor of Science in Pharmaceutical Sciences and Doctor of Pharmacy degrees from the University of Toledo College of Pharmacy and Pharmaceutical Sciences. He completed a PGY-1 Pharmacy Practice Residency at the University of Toledo Medical Center and PGY-2 Solid Organ Transplant Pharmacy Residency at the University of Maryland Medical Center.
Eligibility Requirements
An applicant for board certification in Solid Organ Transplantation Pharmacy must demonstrate all of the eligibility requirements listed below. All practice and education eligibility requirements must be met before submitting the application. Once all of the requirements below are met, an applicant will be deemed eligible to sit for the Solid Organ Transplantation Pharmacy specialty certification examination. If an applicant achieves a passing score on the Solid Organ Transplantation Pharmacy specialty certification examination, they may use the designation Board-Certified Transplant Pharmacist, or BCTXP.
Refer to the Solid Organ Transplantation Pharmacy Examination Content Outline here for details on eligibility requirements, effective dates, and more.
The rationale for the appropriateness of the requirements for BPS certification programs are based upon the following:
- BPS recognizes individuals who graduate from a recognized school or college of pharmacy within the candidate’s jurisdiction. Those jurisdictions recognize and evaluate programs on the extent to which it accomplishes its stated goals and is consistent with the concept that pharmacy is a unique, personal service profession in the health science field. In the United States, the responsibility for recognizing schools and colleges of pharmacy falls to the Accreditation Council for Pharmacy Education (ACPE).
- The rationale for requiring licensure or registration of pharmacists within their jurisdiction is based upon the fact that for public protection, all pharmacists must be licensed or registered. This is considered a baseline requirement to be a pharmacist specialist. In the United States, BPS recognizes the licensure process administered by the National Association of Boards of Pharmacy (NABP). The National Association of Boards of Pharmacy (NABP) aims to ensure the public’s health and safety through its pharmacist license transfer and pharmacist competence assessment programs. NABP’s member boards of pharmacy are grouped into eight districts that include all 50 United States, the District of Columbia, Guam, Puerto Rico, the Virgin Islands, Bahamas, and all 10 Canadian provinces.
- The experiential component is required to help assure practical application of components of the specialty knowledge being certified. There are multiple pathways to meet the practice experience requirement. The faster eligibility pathways recognize accredited residencies through the American Society of Health System Pharmacists (ASHP). The ASHP residency accreditation program identifies and grants public recognition to practice sites having pharmacy residency training programs that have been evaluated and found to meet the qualifications of one of the ASHP’s residency accreditations standards. Thus, accreditation of a pharmacy residency program provides a means of assurance to residency applicants that a program meets certain basic requirements and is, therefore, an acceptable site for postgraduate training in pharmacy practice in organized health care.
- Passing the BPS pharmacy specialty examination helps assure knowledge consistent with the validated content outline for the BPS specialty.
The appropriateness of the BPS program requirements are consistent with the Council on Credentialing in Pharmacy’s Resource Paper titled: Scope of Contemporary Pharmacy Practice: Roles, Responsibilities, and Functions of Pharmacists and Pharmacy Technicians.
Upcoming Deadlines
Individuals who meet the eligibility requirements for the BCTXP examination can find more information about examination dates and fees for certification examinations here.
Candidate's Guide
The Candidate’s Guide is intended for use by pharmacists who are interested in becoming certified as specialists by BPS in any of the BPS-recognized specialty practice areas. To review critical information for BPS Certification Examinations, visit this page.
Content Outline for BCTXP®
Refer to the Solid Organ Transplantation Pharmacy Examination Content Outline here for details on eligibility requirements, effective dates, and more.
The examination content outline is a product of a job analysis, also known as a role delineation study, that includes discussions with a panel of 15-20 subject matter experts who represent the specialty area. These experts determine the competencies required for safe and effective pharmacy practice in the specialty area and engage board-certified pharmacists through a validation survey for their endorsement of the identified competencies. The job analysis process is conducted every 5 years to help ensure that the competencies in the examination content outline reflect current pharmacy practice in the specialty area.
- Click here to review the BCTXP Job Analysis Summary.
Important Resources
Preparing for the BCTXP® Examination
Certification is a significant differentiator, and the rigorous exam process requires concentrated study. Successful candidates are well prepared, and a number of available resources can assist pre-qualified applicants.
Suggested preparation for the examination might include:
- The study of journal articles, textbooks or other publications related to the Content Outline.
- Attendance at continuing education programs and courses in specialized pharmacy practice.
- Participation in study groups and examination preparation courses.
- Reviewing the sample examination items provided on the BPS website in order for candidates to familiarize themselves with the various item formats which are presented on the exam. Sample question performance should not be interpreted as an indicator of exam performance.
To maintain its strict, independent standards for certification, BPS does NOT provide review information, preparatory courses, or study guides. However, such materials are available from outside organizations, state or local professional associations and colleges of pharmacy. Potential applicants may contact the professional associations noted below for additional study resources.
The Board of Pharmacy Specialties provides the following program listing for informational purposes. This list is not an exhaustive list of options available for examination preparation. BPS does not endorse or provide preparatory courses for Board Certification Examinations.
BPS partners with Pearson to provide the examination. BPS does not have any other partnerships for the certification or recertification application process. BPS partners with professional development program (PDP) providers to provide continuing pharmacy education (CPE) for recertification and the relationship is noted here. Any organization claiming a relationship with BPS for the application process or providing CPE labeled ‘BPS-approved’ outside of the organizations listed should be reported to BPS immediately.
Certification for Applicants Outside the U.S.
BPS would like to offer some helpful tips to candidates outside of the United States in order to make their application experience easier. To learn more about applying for board certification as a pharmacist outside of the U.S., visit this page.
Apply for ADA Accommodations
BPS complies with the relevant provisions of the Americans with Disabilities Act (ADA). For applicants looking to request special accommodations in their application process, more instructions can be found on this page.
Frequently Asked Questions
After review of the BPS Candidates Guide and specialty certification page, some applicants may still have questions. Visit this page to see frequently asked questions from pharmacists pursuing board certification like you!
Sample Examination Items
Sample Items for BCTXP Examinations
The sample examination items for BCTXP examinations are made available by BPS for the purposes of familiarizing certification candidates and other stakeholders with the structure and format of BPS Certification Examinations. This is not meant for use as a self-assessment. Performance on any of these items does not correlate with performance on the actual examination.
The content of these examples is meant to be illustrative of actual examination items, but these items do not appear on the certification examination and are not meant to identify the scope of the examination. For a more comprehensive indication of the scope of the certification examination, please refer to the BCTXP Exam Content Outline.
Examination items are in multiple-choice format. The great majority of examination items are multiple-choice with a single response from among four options. Some examinations may include a small percentage of items that require selection of multiple (three or four) responses from among a larger set of available (up to eight) options. Examinations items may also be supplemented by an image.
View the examination items down below.
Which accurately describes the requirements for all hospitals and for organ and tissue donation in the United States set forth in the Centers for Medicare & Medicaid Services Final Rule?
Correct!
Incorrect!
Correct!
Incorrect!
Correct!
Incorrect!
Correct!
Incorrect!
Correct!
Incorrect!
Correct!
Incorrect!
Home medications include:
| Tacrolimus | 3 mg twice daily |
| Mycophenolate mofetil | 1,000 mg twice daily |
| Prednisone | 5 mg daily |
| Acyclovir | 200 mg twice daily |
| Trimethoprim / sulfamethoxazole | DS three times weekly |
| Azithromycin | 250 mg three times weekly |
Pertinent laboratory results:
| Serum Creatinine (SCr) | 4.1 mg/dL |
| Potassium (K) | 5.5 mEq/L |
| Tacrolimus (C0) | 22.3 ng/mL |
Which is likely the greatest contributor to the elevated tacrolimus C0 level?
Correct!
Incorrect!
Correct!
Incorrect!
Central venous pressure within normal limits
Pulmonary artery pressure significantly elevated
Systemic vascular resistance low Cardiac index within normal limits
Which should be initiated?
Correct!
Incorrect!
Correct!
Incorrect!
Correct!
Incorrect!
Donor serologies at the time of transplant were:
| Hepatitis B Core Antibody | Positive |
| Hepatitis B Surface Antigen | Negative |
| Hepatitis B Surface Antibody | Negative |
Past medical history is unremarkable other than osteoporosis, for which zoledronic acid is infused yearly. What treatment should be initiated?
Correct!
Incorrect!
Share the quiz to show your results !
Subscribe to see your results
I got %%score%% of %%total%% right
Loading...
Recertification Requirements for BCTXP
Pharmacists who earn the designation Board-Certified Transplant Pharmacist (BCTXP®) will be required to maintain their certification over a seven-year period by completing one of the following recertification pathways:
Option One: Recertification Examination
- For BCTXP® with certification beginning January 1, 2023 or earlier: Achieve a passing score on the recertification examination administered by BPS.
- For BCTXP® with certification beginning January 1, 2024 or later: Achieve a passing score on the recertification examination administered by BPS and self-report up to 20 units of continuing professional development (CPD). Assessed continuing pharmacy education (CPE) from BPS-approved professional development programs can also satisfy this requirement. For more information on CPD, review the FAQ. To maintain an active certification in good standing, a minimum of two units of assessed CPE from BPS-approved professional development programs or self-reported CPD must be reported each year.
OR
Option Two: Professional Development Program
- For BCTXP with certification beginning January 1, 2023 or earlier: recertification via professional development program requires 100 units of assessed CPE from BPS-approved professional development programs offered by:
- The American College of Clinical Pharmacy (ACCP) in collaboration with the American Society of Health Systems Pharmacists (ASHP)
- BCTXP may participate in recertification from BPS-approved BCTXP programs.
BCTXP® who participated in the self-reporting period must complete the remaining CPE (for 100 total) by earning assessed CPE from BPS-approved professional development programs offered by the above.
- For BCTXP® with certification beginning January 1, 2024 or later: recertification via professional development program requires 100 units. Earn at least 80 units of assessed continuing pharmacy education (CPE) from BPS-approved professional development programs and self-report up to 20 units of continuing professional development (CPD) by the end of the 7 year recertification cycle (assessed CPE can also satisfy this requirement).*
- The American College of Clinical Pharmacy (ACCP) in collaboration with the American Society of Health Systems Pharmacists (ASHP)
- * A minimum of 2 units of CPD or BPS-approved, assessed CPE must be earned annually, regardless of recertification pathway
- BCTXP may participate in recertification from BPS-approved BCTXP programs.
Click here to view a simplified comparison infographic to learn more about the differences between the CPE and CPD recertification frameworks.
| Year certified/recertified | New cycle start (begin earning recert units) | Cycle expiration (deadline to meet recert reqs) | Units required (PDP = professional development program) |
| 2019 | 1/1/2020 | 12/31/2026 | 100 units assessed CPE via BPS-approved PDP |
| 2020 | 1/1/2021 | 12/31/2027 | 100 units assessed CPE via BPS-approved PDP |
| 2021 | 1/1/2022 | 12/31/2028 | 100 units assessed CPE via BPS-approved PDP |
| 2022 | 1/1/2023 | 12/31/2029 | 100 units assessed CPE via BPS-approved PDP |
| 2023 | 1/1/2024 | 12/31/2030 | 100 units (80 units assessed CPE via BPS-approved PDP + 20 units CPD) |
| 2024 onward | 1/1/2025 onward | 12/31/2031 onward | 100 units (80 units assessed CPE via BPS-approved PDP + 20 units CPD) |
For full details regarding recertification, please refer to the BPS Recertification Guide.
Board-Certified Transplant Pharmacists® are required to pay the BPS Annual Certification Maintenance Fee of $125 each year for years one through six and the $400 recertification fee in year seven. Individuals with more than one BPS certification are assessed one BPS Annual Certification Maintenance Fee each year.
Upcoming Deadlines
Candidates are required to recertify every 7 years. Certificants must submit their recertification application no later than the deadline of August 17. BPS encourages candidates to submit their recertification application as early as January 1 of their recertification year.
Candidates who intend to recertify via examination should note the availability of the recertification examination and related application deadlines. Candidates recertifying their BCTXP credential by examination can find more information about examination dates and fees here.
Candidates who intend to recertify via continuing pharmacy education (CPE) MUST submit their recertification application by the deadline date of August 17 even if they have not completed their CPE requirements.
The deadline to complete the required CPE for recertification is December 31 for all specialties. The board-certified pharmacist is responsible for submitting an application that is completely and accurately filled out. Incomplete and/or unpaid applications will not be processed.
Recertification Guide
CPE Providers
BCTXP with certification beginning January 1, 2023 or earlier: recertification via professional development program requires 100 units of assessed CPE from BPS-approved professional development programs offered by:
BCTXP who participated in the self-reporting period must complete the remaining CPE (for 100 total) by earning assessed CPE from BPS-approved professional development programs offered by the above.
BCTXP with certification beginning January 1, 2024 or later: recertification via professional development program requires 100 units. Earn at least 80 units of assessed continuing pharmacy education (CPE) from a BPS-approved professional development programs and self-report up to 20 units of continuing professional development (CPD) by the end of the 7 year recertification cycle (assessed CPE can also satisfy this requirement).*
*A minimum of 2 units of CPD or BPS-approved, assessed CPE must be earned annually, regardless of recertification pathway.
Content Outline for BCTXP®
Refer to the Solid Organ Transplantation Pharmacy Examination Content Outline here for details on eligibility requirements, effective dates, and more.
The examination content outline is a product of a job analysis, also known as a role delineation study, that includes discussions with a panel of 15-20 subject matter experts who represent the specialty area. These experts determine the competencies required for safe and effective pharmacy practice in the specialty area and engage board-certified pharmacists through a validation survey for their endorsement of the identified competencies. The job analysis process is conducted every 5 years to help ensure that the competencies in the examination content outline reflect current pharmacy practice in the specialty area.
- Click here to review the BCTXP Job Analysis Summary.
Important Resources
Logging CPD Activities (Video)
Watch a step-by-step video walkthrough of how to report CPD activities in MyBPS once a certificant begins a new certification cycle. For CPD categories and descriptions, see the “How will CPD activities contribute to recertification?” question in the CPD FAQs.
CPD Annual Reflection and Plan (ARP) Sample
Click here to view a sample Annual Reflection and Plan (ARP) to help guide formatting and structure for your CPD annual reflection and learning plan.
CPD Activity Evaluation Sample
Click here to view a sample CPD activity evaluation (scholarly activity) to help guide how evaluations may be documented for CPD credit. This sample is for guidance and is not the only acceptable format.
Frequently Asked Questions
After review of the BPS Recertification Guide and specialty page, some applicants may still have questions. Visit this page to see frequently asked questions from pharmacists renewing their board certification like you!
Sample Examination Items
Sample Items for BCTXP Examinations
The sample examination items for BCTXP examinations are made available by BPS for the purposes of familiarizing certification candidates and other stakeholders with the structure and format of BPS Certification Examinations. This is not meant for use as a self-assessment. Performance on any of these items does not correlate with performance on the actual examination.
The content of these examples is meant to be illustrative of actual examination items, but these items do not appear on the certification examination and are not meant to identify the scope of the examination. For a more comprehensive indication of the scope of the certification examination, please refer to the BCTXP Exam Content Outline.
Examination items are in multiple-choice format. The great majority of examination items are multiple-choice with a single response from among four options. Some examinations may include a small percentage of items that require selection of multiple (three or four) responses from among a larger set of available (up to eight) options. Examinations items may also be supplemented by an image.
View the examination items down below.
Which accurately describes the requirements for all hospitals and for organ and tissue donation in the United States set forth in the Centers for Medicare & Medicaid Services Final Rule?
Correct!
Incorrect!
Correct!
Incorrect!
Correct!
Incorrect!
Correct!
Incorrect!
Correct!
Incorrect!
Correct!
Incorrect!
Home medications include:
| Tacrolimus | 3 mg twice daily |
| Mycophenolate mofetil | 1,000 mg twice daily |
| Prednisone | 5 mg daily |
| Acyclovir | 200 mg twice daily |
| Trimethoprim / sulfamethoxazole | DS three times weekly |
| Azithromycin | 250 mg three times weekly |
Pertinent laboratory results:
| Serum Creatinine (SCr) | 4.1 mg/dL |
| Potassium (K) | 5.5 mEq/L |
| Tacrolimus (C0) | 22.3 ng/mL |
Which is likely the greatest contributor to the elevated tacrolimus C0 level?
Correct!
Incorrect!
Correct!
Incorrect!
Central venous pressure within normal limits
Pulmonary artery pressure significantly elevated
Systemic vascular resistance low Cardiac index within normal limits
Which should be initiated?
Correct!
Incorrect!
Correct!
Incorrect!
Correct!
Incorrect!
Donor serologies at the time of transplant were:
| Hepatitis B Core Antibody | Positive |
| Hepatitis B Surface Antigen | Negative |
| Hepatitis B Surface Antibody | Negative |
Past medical history is unremarkable other than osteoporosis, for which zoledronic acid is infused yearly. What treatment should be initiated?
Correct!
Incorrect!
Share the quiz to show your results !
Subscribe to see your results
I got %%score%% of %%total%% right
Loading...
Testimonials

Transplant is an umbrella term used to describe a practice area with subspecialties. Depending on pharmacists’ backgrounds, training, or institutions, their experiences vary – pediatrics, adults, abdominal, thoracic, QAPI, and more. Board certification of BCTXP allows foundational awareness of colleagues’ unifying expertise, beyond practice experiences, aiding specialty progression.

I sought BPS certification in Solid Organ Transplantation as soon as the newly created exam was offered as a means of expressing my commitment to excellence both to my patients and my peers. Board certification is a distinguishing career achievement that all clinical pharmacists should seriously consider.

To me, board certification is a journey that extends beyond a credential – it’s a commitment to lifelong learning, a dedication to excellence, and a responsibility to positively impact patient care.

Maintaining a board certification enables me to become a residency program director, which has been a goal since I was a PGY2. I look forward to continuing to mentor future pharmacists, and them knowing they can put their trust in me as a board certified professional.

My certifications have opened doors to new roles and patient care, leadership, and educational opportunities. The certification process has helped me stay updated with treatment recommendations and become a stronger clinician and educator. As my career has evolved, my board certification has helped me grow.
Certification Verification
BPS offers the ability to search and verify a Board-Certified Pharmacist by name or credential number.